IPO

CRISPR Therapeutics, the company started by a pioneer of the gene editing technology, plans to raise $90 million from an initial public offering.

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.

The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 

The drought has ended for biotech companies seeking to join the public market, but whether this upward swing will last is anybody’s guess.

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.